Related Experiment Video
Updated: May 3, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Telehealth insulin titration in adults with diabetes: a randomized controlled trial comparing bluetooth-enabled
Xia Lian1,2, Hui Ling Liew3, Ying Shan Lee3
1Department of Nursing, Tan Tock Seng Hospital, Singapore, Singapore.
Objective:
Blood glucose self-monitoring is crucial for individuals with diabetes mellitus and on insulin therapy to ensure safe glycemic control and optimal treatment outcomes. This study evaluates the effectiveness of Bluetooth-enabled glucometers (BTG) versus Traditional glucometers (TG) in a telehealth insulin titration program for individuals with diabetes.
Methods:
This 24-week, open-label, randomized controlled trial enrolled 120 participants with diabetes from a tertiary hospital. Participants, aged 21-70 years, who required either insulin initiation or intensification were randomly assigned to either the BTG or TG group. Both groups received three biweekly teleconsultations with Diabetes Nurse Educators for insulin dose adjustments, followed by two clinic visits at three-month intervals.
Results:
Participants were predominantly male, Chinese, and diagnosed with Type 2 diabetes. Both groups demonstrated significant reductions in glycated hemoglobin (HbA1c) throughout the study. The TG group achieved HbA1c reductions of 2.8% at Week 12 and 3.1% at Week 24 (both p < 0.001), while the BTG group showed reductions of 2.23% and 2.18% respectively (both p < 0.001). There were no significant between-group differences in HbA1c at any time point. However, the BTG group showed significantly fewer emergency department visits than TG (4.1% vs. 16.7%, p = 0.039). Both groups demonstrated improvements in diabetes-related distress, with no significant differences between groups.
Conclusion:
BTG did not demonstrate glycemic superiority over TG in telehealth insulin titration; however, its association with reduced emergency department visits suggests potential benefits for healthcare utilization. Future studies should investigate the integration of BTG with comprehensive diabetes care platforms, with a focus on long-term outcomes and cost-effectiveness.
Clinical Trial Registration:
https://www.isrctn.com/ISRCTN69173566, Identifier: ISRCTN69173566.
More Related Videos
08:01A Method for Manipulating Blood Glucose and Measuring Resulting Changes in Cognitive Accessibility of Target Stimuli
Published on: August 12, 2016
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
Related Concept Videos
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones